Adaptive Biotechnologies Highlights New Data at 2025 ASCO Annual Meeting and EHA 2025 Congress Demonstrating How clonoSEQ® MRD Assessment is Optimizing Patient Care and Drug Development in Lymphoid Cancers
30 scientific abstracts will be presented using clonoSEQ for MRD assessment across multiple types of blood cancers
SEATTLE, May 30, 2025 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced that its next-generation sequencing (NGS)-based clonoSEQ® test for measurable residual disease (MRD) assessment will be included in 30 presentations, including a total of 14 oral presentations, across the American Society of Clinical Oncology (ASCO) Annual Meeting taking place May 30-June 3 in Chicago and the European Hematology Association (EHA) Congress taking place June 12-15 in Milan. These presentations include notable new data supporting the clinical actionability of clonoSEQ in both multiple myeloma (MM) and chronic lymphocytic leukemia (CLL).
"The breadth of new MRD evidence being shared across various blood cancer types at ASCO and EHA this year highlights the transformative impact MRD is having on clinical care and drug development," said Susan Bobulsky, Chief Commercial Officer, MRD, Adaptive Biotechnologies. "These data presentations are a testament to the central role that clonoSEQ MRD testing now plays in clinical management and drug development across lymphoid cancers, particularly when combined with several clonoSEQ data presentations in diffuse large B-cell lymphoma (DLBCL) anticipated at the 18th International Conference on Malignant Lymphoma (iCML) on June 17-21, 2025 in Lugano, Switzerland."
Selected presentations include:Results from MIDAS, a phase 3 randomized study of 718 transplant-eligible, newly diagnosed multiple myeloma (NDMM) patients, demonstrate the use of MRD status to guide therapy post-induction. (ASCO Abstract 7500, June 3, 9:45-9:57 a.m. CDT, S100bc, McCormick Place Convention Center)
Interim data from ADVANCE, a phase 2 randomized study of 306 transplant-eligible patients with NDMM shows the impact of MRD-guided assessments post-induction (ASCO Abstract 7503, June 3, 10:21-10:33 a.m. CDT, S100bc, McCormick Place Convention Center)
Interim results from VENETOSTOP, a phase 2 study of 66 CLL patients, report the use of MRD status to shorten duration of venetoclax-based therapy. (EHA Abstract PS1568, June 14, 6:30 p.m. CEST, Poster Hall, Milano Convention Centre)Results from the phase 3 IsKia study of 151 transplant-eligible NDMM patients demonstrates increased rates of sustained MRD negativity at 10-6 with isatuximab plus carfilzomib, lenalidomide, and dexamethasone. (ASCO Abstract 7502, June 3, 10:09-10:21 a.m. CDT, S100bc, McCormick Place Convention Center)
Follow-up data from PERSEUS, a phase 3 trial of 709 transplant-eligible patients with NDMM reports the impact of sustained MRD negativity status on progression free survival (PFS) with subcutaneous daratumumab plus bortezomib, lenalidomide and dexamethasone (D-VRd) induction and DR maintenance. (ASCO Abstract 7501, June 3, 9:57-10:09 a.m. CDT, S100bc, McCormick Place Convention Center)
Results from DREAMM-8, a Phase 3 study in 302 patients with relapsed or refractory multiple myeloma, found superior PFS and higher MRD negativity rates in patients treated with belantamab mafodotin plus pomalidomide and dexamethasone (BPd) as compared to standard-of-care pomalidomide, bortezomib, and dexamethasone (PVd). (ASCO Abstract 7515, June 2, 9:00-9:06 a.m. CDT E450b, McCormick Place Convention Center)
Data to be presented at ASCO:
Presentation Type and Number
Title
Presentation Timing
B-Cell Acute Lymphoblastic Leukemia
Poster Presentation6540
Initial results from a phase II study of dose-adjusted etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin (DA-EPOCH) ± rituximab (R) + tafasitamab (tafa) for adults with newly-diagnosed (ND) Philadelphia chromosome negative (Ph-) B lymphoblastic leukemia (B-ALL)
Sunday, June 19 a.m.-12 p.m. CDT
Poster Presentation6543
Brexucabtagene autoleucel (Brexu-cel) as consolidation treatment in adults with B-cell acute lymphoblastic leukemia
Sunday, June 19 a.m.-12 p.m. CDT
Multiple Myeloma
Oral Presentation7500*
MRD-driven strategy following IsaKRD induction in transplant-eligible NDMM: Primary endpoints of the phase 3 MIDAS trial
Tuesday, June 39:45-9:57 a.m. CDT
Oral Presentation7501
Subcutaneous daratumumab (Dara) + bortezomib/lenalidomide/dexamethasone (VRd) with Dara + lenalidomide (DR) maintenance in transplant-eligible (TE) patients with newly diagnosed multiple myeloma (NDMM): Analysis of sustained minimal residual disease negativity in the phase 3 PERSEUS trial
Tuesday, June 39:57-10:09 a.m. CDT
Oral Presentation7502
Sustained MRD negativity in patients with newly diagnosed multiple myeloma treated with carfilzomib-lenalidomide-dexamethasone with or without isatuximab (phase III IsKia trial)
Tuesday, June 310:09-10:21 a.m. CDT
Oral Presentation7503*
Randomized, multi-center study of carfilzomib, lenalidomide, and dexamethasone (KRd) with or without daratumumab (D) in patients with newly diagnosed multiple myeloma (NDMM): The ADVANCE clinical trial
Tuesday, June 310:21-10:33 a.m. CDT
Oral Presentation7507*
Long-term (≥5 year) remission and survival after treatment with ciltacabtagene autoleucel (cilta-cel) in CARTITUDE-1 patients (pts) with relapsed/refractory multiple myeloma (RRMM)
Tuesday, June 311:57 a.m.-12:09 p.m. CDT
Oral Presentation7515
Minimal residual disease (MRD) negativity (neg) in patients (pts) with relapsed or refractory multiple myeloma (RRMM) treated with belantamab mafodotin plus pomalidomide and dexamethasone (BPd) vs pomalidomide, bortezomib, and dexamethasone (PVd): Analysis from the DREAMM-8 trial
Monday, June 29-9:06 a.m. CDT
Oral Presentation7516
Daratumumab plus bortezomib, lenalidomide, and dexamethasone (DVRd) in patients with newly diagnosed multiple myeloma (NDMM): Subgroup analysis of transplant-ineligible (TIE) patients in the phase 3 CEPHEUS study
Monday, June 29:06-9:12 a.m. CDT
ASCO Oral Presentation7517*
Isatuximab, bortezomib, lenalidomide, and dexamethasone (Isa-VRd) in newly diagnosed multiple myeloma (NDMM): Outcomes in patients with 1q21+ status in the phase 3 IMROZ study
Monday, June 29:12-9:18 a.m. CDT
Poster Presentation7529
Daratumumab + bortezomib, lenalidomide, and dexamethasone (DVRd) vs VRd in transplant-ineligible (TIE)/transplant-deferred (TD) newly diagnosed multiple myeloma (NDMM): Phase 3 CEPHEUS trial cytogenetic subgroup analysis
Sunday, June 19 a.m.-12 p.m. CDT
Poster Presentation7535
Carfilzomib, lenalidomide, and dexamethasone (KRd) as maintenance therapy after autologous stem-cell transplantation (ASCT) in patients with newly diagnosed multiple myeloma (NDMM)
Sunday, June 19 a.m.-12 p.m. CDT
ASCO Poster Presentation7551*
Positron emission tomography with computed tomography (PET/CT) and minimal residual disease (MRD) for efficacy assessment in transplant-ineligible newly diagnosed myeloma (Ti NDMM) patients (pts): IMROZ analysis
Sunday, June 19 a.m.-12 p.m. CDT
Data to be presented at EHA:
Presentation Type and Number
Title
Presentation Timing
B-Cell Acute Lymphoblastic Leukemia
Oral PresentationS112
Safety and efficacy of single-agent subcutaneous blinatumomab in adults with relapsed/refractory (R/R) b-cell acute lymphoblastic leukemia (B-ALL): results from a phase 1/2 dose expansion study
Sunday, June 1511:30-11:45 a.m. CEST
Oral PresentationS117
Safety and efficacy of AZD0486 in adolescent and adult patients with relapsed or refractory b-cell acute lymphoblastic leukemia: early results from the phase 1/2 SYRUS study
Friday, June 135:30-5:45 p.m. CEST
Poster PresentationPF372
Donor-derived, allogeneic CD19/CD22-CAR T cells with myeloablative graft-engineered Allo-HCT for high-risk B-ALL
Friday, June 136:30 p.m. CEST
Chronic Lymphocytic Leukemia
Poster PresentationPF575
Preliminary results of the ongoing multicenter, phase 2 study of retreatment with venetoclax plus obinutuzumab (ReVenG) in patients with recurrent chronic lymphocytic leukemia (CLL)
Friday, June 136:30 p.m. CEST
Poster PresentationPS1568
Using minimal residual disease status to guide venetoclax treatment duration in patients with chronic lymphocytic leukemia: interim results from the phase II VENETOSTOP study
Saturday, June 146:30 p.m. CEST
Follicular Lymphoma
Poster PresentationPF881
Epcoritamab monotherapy demonstrates deep and durable responses at 3-year follow-up in patients with relapsed/refractory follicular lymphoma
Friday, June 136:30 p.m. CEST
Poster PresentationPS2150
4-year update of phase 2 ELARA trial: clinical outcomes of tisagenlecleucel in patients (pts) with high-risk relapsed/refractory follicular lymphoma (R/R FL)
Saturday, June 146:30 p.m. CEST
Mantle Cell Lymphoma
Poster PresentationPF882
Minimal residual disease with bendamustine-rituximab with or without acalabrutinib in patients with previously untreated mantle cell lymphoma: results from the phase 3 ECHO trial
Friday, June 136:30 p.m. CEST
Multiple Myeloma
Oral PresentationS201
Phase 2 registrational study of anitocabtagene autoleucel for relapsed and/or refractory multiple myeloma (RRMM): updated results from IMMAGINE-1
Saturday, June 145:15-5:30 p.m. CEST
Oral PresentationS205*
Minimal residual disease-driven strategy following isatuximab-carfilzomib-lenalidomide-dexamethasone induction in transplant-eligible newly diagnosed multiple myeloma: Primary endpoints of the phase 3 MIDAS trial
Sunday, June 1511:00-11:15 a.m. CEST
Oral Presentation S207*
A randomized, multi-center study of carfilzomib, lenalidomide and dexamethasone (KRd) with or without daratumumab (D) for the treatment of patients with newly diagnosed multiple myeloma (NDMM): The ADVANCE clinical trial
Sunday, June 1511:30-11:45 a.m. CEST
Oral PresentationS208*
Analysis of sustained MRD negativity in patients with newly diagnosed multiple myeloma treated with carfilzomib-lenalidomide-dexamethasone with or without isatuximab (phase III IsKia trial)
Sunday, June 1511:45 a.m.-12 p.m. CEST
Poster PresentationPF727
Isa-vrd improves outcomes in high-risk (HR) newly diagnosed transplant-ineligible multiple myeloma (NDMM TI) using the IMS/IMWG consensus HR definition: results from the BENEFIT phase 3 trial (IFM 2020-05)
Friday, June 136:30 p.m. CEST
Poster Presentation PF729*
Isatuximab, bortezomib, lenalidomide, and dexamethasone (Isa-VRd) in newly diagnosed multiple myeloma (NDMM): outcomes in patients with 1q21+ status in the phase 3 IMROZ study
Friday, June 136:30 p.m. CEST
Poster PresentationPF750
Isatuximab, bortezomib, lenalidomide, dexamethasone (Isa-VRd) in patients with transplant-ineligible (TI) newly diagnosed myeloma (NDMM) and plasmacytomas: IMROZ subgroup analysis
Friday, June 136:30 p.m. CEST
Poster PresentationPF754
Interim analysis of MRD-guided maintenance therapy with belantamab mafodotin and lenalidomide after Auto-HCT in newly diagnosed multiple myeloma
Friday, June 136:30 p.m. CEST
Poster Presentation PS1722*
Positron emission tomography with computed tomography and minimal residual disease for efficacy assessment in transplant-ineligible newly diagnosed myeloma patients: IMROZ analysis
Saturday, June 146:30 p.m. CEST
*Indicates data to be presented at both ASCO and EHA.
About clonoSEQ clonoSEQ® is the first and only FDA-cleared in vitro diagnostic (IVD) test for detecting and tracking minimal (or measurable) residual disease (MRD) in patients with multiple myeloma (MM) or B-cell acute lymphoblastic leukemia (B-ALL) using bone marrow, and in patients with chronic lymphocytic leukemia (CLL) using blood or bone marrow. clonoSEQ is also available in diffuse large B-cell lymphoma (DLBCL), mantle cell lymphoma (MCL) and other lymphoid cancers and specimen types as a CLIA-validated laboratory developed test (LDT). clonoSEQ is covered by Medicare for MM, CLL, ALL, DLBCL and MCL.
clonoSEQ identifies and quantifies DNA sequences in malignant cells—detecting one cancer cell in one million healthy cells—to help clinicians and researchers assess and monitor MRD with precision over time. It delivers standardized, sensitive results that inform treatment decisions, predict outcomes, and detect relapses earlier.
clonoSEQ is CE-marked under the EU In Vitro Diagnostic Regulation (IVDR). For intended use details in the EU, see the instructions for use, available on request.
To review the FDA-cleared uses of clonoSEQ, visit clonoSEQ.com/technical-summary.
About Adaptive Biotechnologies Adaptive Biotechnologies ("we" or "our") is a commercial-stage biotechnology company focused on harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. We believe the adaptive immune system is nature's most finely tuned diagnostic and therapeutic for most diseases, but the inability to decode it has prevented the medical community from fully leveraging its capabilities. Our proprietary immune medicine platform reveals and translates the massive genetics of the adaptive immune system with scale, precision and speed. We apply our platform to partner with biopharmaceutical companies, inform drug development, and develop clinical diagnostics across our two business areas: Minimal Residual Disease (MRD) and Immune Medicine. Our commercial products and clinical pipeline enable the diagnosis, monitoring, and treatment of diseases such as cancer, autoimmune disorders, and infectious diseases. Our goal is to develop and commercialize immune-driven clinical products tailored to each individual patient.
Forward Looking Statements This press release contains forward-looking statements that are based on management's beliefs and assumptions and on information currently available to management. All statements contained in this release other than statements of historical fact are forward-looking statements, including statements regarding our ability to develop, commercialize and achieve market acceptance of our current and planned products and services, our research and development efforts, and other matters regarding our business strategies, use of capital, results of operations and financial position, and plans and objectives for future operations.
In some cases, you can identify forward-looking statements by the words "may," "will," "could," "would," "should," "expect," "intend," "plan," "anticipate," "believe," "estimate," "predict," "project," "potential," "continue," "ongoing" or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. These statements involve risks, uncertainties and other factors that may cause actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements. These risks, uncertainties and other factors are described under "Risk Factors," "Management's Discussion and Analysis of Financial Condition and Results of Operations" and elsewhere in the documents we file with the Securities and Exchange Commission from time to time. We caution you that forward-looking statements are based on a combination of facts and factors currently known by us and our projections regarding the future, about which we cannot be certain. As a result, the forward-looking statements may not prove to be accurate. The forward-looking statements in this press release represent our views as of the date hereof. We undertake no obligation to update any forward-looking statements for any reason, except as required by law.
ADAPTIVE INVESTORS Karina Calzadilla, Vice President, Investor Relations and FP&A 201-396-1687 investors@adaptivebiotech.com
ADAPTIVE MEDIAErica Jones, Associate Corporate Communications Director206-279-2423media@adaptivebiotech.comSign in to access your portfolio
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
16 minutes ago
- Yahoo
QDWN, VIXY Among ETFs Posting Biggest Declines in May 2025
Exchange-traded funds utilizing options strategies and volatility exposure led May's worst-performers among non-leveraged funds, with the DailyDelta Q100 Downside Option Strategy ETF (QDWN) falling the most at 43%, according to FactSet data. With $192,500 in assets under management, QDWN pursues short-term bearish bets on the Nasdaq-100 Index through put options purchases, according to FactSet. The actively managed strategy seeks capital appreciation while limiting single-day risk to 10% or less of net asset value. Posting the second-worst performance is the YieldMax Short COIN Option Income Strategy ETF (FIAT), which declined 33%, according to FactSet. Holding $49.8 million in assets, the fund aims to provide current income and inverse exposure to Coinbase Global, Inc. (COIN) stock through a synthetic covered put strategy. Volatility-focused products also struggled during May. Both the ProShares VIX Short-Term Futures ETF (VIXY) and iPath Series B S&P 500 VIX Short-Term Futures ETN (VXX) declined 27%, according to FactSet data. Tracking futures contracts on the CBOE Volatility Index with average one-month maturity, the VIXY fund holds $129.7 million in assets. With $389.3 million in assets, the VXX product provides similar short-term VIX futures exposure but operates as an exchange-traded note rather than a traditional ETF structure, according to FactSet. Worst-Performing ETFs of May 2025—Source: FactSet The YieldMax Short N100 Option Income Strategy ETF (YQQQ) posted a 13% loss, according to FactSet. With $11.7 million in assets, the fund employs a synthetic covered put strategy targeting inverse exposure to the Nasdaq-100 Index while generating monthly income. Rounding out the top five decliners is the WisdomTree Efficient Gold Plus Gold Miners Strategy Fund (GDMN), which declined 10%, according to FactSet. This $36.6 million actively-managed fund provides concentrated exposure to gold through both mining company equities and U.S.-listed gold futures contracts. Mining-focused ETFs continued the decline pattern as the iShares MSCI Global Silver Miners ETF (SLVP) fell 9%, according to FactSet. Holding $282.9 million in assets, the fund tracks a market-cap-weighted index of global companies that earn the majority of their revenues from silver mining. Multiple funds tied at 8% declines. Through an actively managed market-neutral strategy, the AGF U.S. Market Neutral Anti-Beta Fund (BTAL) takes long positions in low-beta U.S. stocks offset by short positions in high-beta stocks, with $318.6 million in assets. Natural gas exposure also hurt performance as the United States Natural Gas Fund LP (UNG) fell 8%, according to FactSet. With $363.3 million in assets, the fund holds near-month futures contracts in natural gas delivered at Henry Hub, Louisiana, rolling expiring contracts to maintain front-month exposure. Automated trading strategies struggled as the TradersAI Large Cap Equity & Cash ETF (HFSP) posted an 8% decline, according to FactSet. With $848,200 in assets, the fund uses proprietary algorithms with human oversight to trade S&P 500 Index e-mini futures positions based on intraday price movements. Completing the worst-performers list is the Themes Gold Miners ETF (AUMI), which also lost 8%, according to FactSet. With $10.4 million in assets, the fund tracks a market-cap-weighted index of the 30 largest gold-mining companies | © Copyright 2025 All rights reserved
Yahoo
18 minutes ago
- Yahoo
StealthCores Joins Microchip Partner Program to Deliver Advanced Security for PolarFire FPGA and SoC Platforms
Partnership delivers optimized encryption solutions for mission-critical applications Gainesville, FL, June 04, 2025 (GLOBE NEWSWIRE) -- StealthCores, a provider of advanced encryption IP for secure systems, has joined the Microchip Partner Program to deliver cutting-edge protection for PolarFire® FPGA and PolarFire SoC platforms. The partnership enables customers to leverage StealthCores' specialized encryption technologies, StealthAES and StealthMem, which are now fully optimized for the PolarFire architecture. These solutions complement Microchip's built-in security features, providing additional performance and capabilities while maintaining the highest levels of protection against side-channel attacks. "Our close collaboration with Microchip allows us to deliver security solutions that are precisely tailored to the unique capabilities of the PolarFire platform," said Stuart Audley, President of StealthCores. "As security threats continue to evolve, this partnership ensures that customers have access to the most advanced encryption technologies available for their mission-critical applications." StealthAES implements high-performance AES-GCM encryption secured with advanced countermeasures for enhanced protection on PolarFire platforms, while StealthMem delivers comprehensive memory encryption across RAM, flash, and PCIe® NVMe® interfaces. Together, these solutions address the growing need for comprehensive data protection in edge computing, communications infrastructure, defense systems, and industrial applications. The partnership also enables StealthCores to offer PolarFire implementation services, helping customers integrate advanced security features using the embedded Athena TeraFire cryptoprocessor and PCIe subsystem. This approach enables efficient integration of even the most complex security requirements. "As security becomes a non-negotiable in defense, industrial, and communications sectors, our partnership with StealthCores ensures developers have direct access to field-tested encryption tools that meet real-world requirements," said Shakeel Peera Vice President of Marketing and Strategy for Microchip's FPGA business unit. "By leveraging StealthAES and StealthMem technologies in Microchip's PolarFire FPGA architecture, we're pushing the boundaries of what's possible in FPGA security." StealthCores' solutions are now available for PolarFire FPGA and SoC platforms through the Microchip Partner Program. About StealthCores StealthCores develops advanced security IP for FPGAs and ASICs, delivering practical, high-performance cryptographic solutions with built-in countermeasures against side-channel attacks. Backed by decades of industry experience and purpose-built IP, StealthCores enables customers to secure critical systems with confidence. Learn more at or contact us at info@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
18 minutes ago
- Yahoo
Newmark Facilitates $210 Million Sale of Iconic Office Tower in Downtown Los Angeles' Financial District
LOS ANGELES, June 4, 2025 /PRNewswire/ -- Newmark Group, Inc. (Nasdaq: NMRK) ("Newmark" or "the Company"), a leading commercial real estate advisor and service provider to large institutional investors, global corporations, and other owners and occupiers, announces the company has arranged the sale of 601 South Figueroa Street — also known as 601 Fig or Fig at Wilshire — a 1,041,315-square-foot high-rise office tower in Downtown Los Angeles. The asset sold for $210 million, equating to a price of approximately $202 per square foot. Newmark Co-Head of U.S. Capital Markets Kevin Shannon and Vice Chairmen Ken White, Rob Hannan, Laura Stumm and Michael Moll and Director Alex Beaton represented the undisclosed seller. Newmark Executive Vice Chairman and Head of International Capital Markets Alex Foshay worked alongside the aforementioned Newmark team. Newmark Co-President, Global Debt & Structured Finance Jonathan Firestone, Vice Chairman Blake Thompson and Director Henry Cassiday provided support on debt strategy and financing considerations throughout the transaction process. Mark Schuessler, Jordon Garcia and Sean Fulp of Colliers advised the buyer, Uncommon Developers. "601 Fig is one of LA's truly iconic office buildings at the renowned corner of Wilshire Boulevard and Figueroa," said Shannon. "This investment sale will provide long term upside for yet another patient and well-capitalized family office buyer." "Since its completion in 1990, 601 Fig has always had 'power business card' status in the city," added Hannan. "Standing in its majestic 75-foot lobby, you get the sense that you are in a special place, a place where a big deal is about to be made. Uncommon Developers will continue 601 Fig's reputation as one of LA's premier corporate environments." Located at the intersection of Figueroa Street and Wilshire Boulevard, Fig at Wilshire is a 52-story office tower with a distinctive octagonal design and glass crown, contributing to Downtown Los Angeles' skyline. The property offers a range of amenities, including dual lobbies with a 75-foot atrium, a modern fitness center, a WiFi-enabled open-air plaza and onsite dining options, including a coffee shop and fast-casual restaurant. At the time of sale, the building was 72% leased to tenants from diverse industries, with many representing strong national and regional credit profiles. Professional services firm PricewaterhouseCoopers (PwC) serves as the anchor tenant. The property's prime location provides easy access to key Downtown Los Angeles destinations, including Arena, Microsoft Theater, LA Live, Fig at 7th and the 7th Street Metro station, a central rail hub. About Newmark Newmark Group, Inc. (Nasdaq: NMRK), together with its subsidiaries ("Newmark"), is a world leader in commercial real estate, seamlessly powering every phase of the property life cycle. Newmark's comprehensive suite of services and products is uniquely tailored to each client, from owners to occupiers, investors to founders, and startups to blue-chip companies. Combining the platform's global reach with market intelligence in both established and emerging property markets, Newmark provides superior service to clients across the industry spectrum. For the twelve months ended March 31, 2025, Newmark generated revenues of over $2.8 billion. As of March 31, 2025, Newmark and its business partners together operated from 165 offices with approximately 8,100 professionals across four continents. To learn more, visit or follow @newmark. Discussion of Forward-Looking Statements about Newmark Statements in this document regarding Newmark that are not historical facts are "forward-looking statements" that involve risks and uncertainties, which could cause actual results to differ from those contained in the forward-looking statements. These include statements about the Company's business, results, financial position, liquidity, and outlook, which may constitute forward-looking statements and are subject to the risk that the actual impact may differ, possibly materially, from what is currently expected. Except as required by law, Newmark undertakes no obligation to update any forward-looking statements. For a discussion of additional risks and uncertainties, which could cause actual results to differ from those contained in the forward-looking statements, see Newmark's Securities and Exchange Commission filings, including, but not limited to, the risk factors and Special Note on Forward-Looking Information set forth in these filings and any updates to such risk factors and Special Note on Forward-Looking Information contained in subsequent reports on Form 10-K, Form 10-Q or Form 8-K. View original content to download multimedia: SOURCE Newmark Group, Inc. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
